Franklin Resources Inc Terns Pharmaceuticals, Inc. Transaction History

Franklin Resources Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.54 - $8.2 $5.72 Million - $10.3 Million	-1,259,054 Reduced 52.86%	1,122,842 $7.65 Million
Q1 2024 May 13, 2024	BUY	$4.86 - $8.19 $359,941 - $606,567	74,062 Added 3.21%	2,381,896 $15.6 Million
Q4 2023 Feb 09, 2024	BUY	$3.37 - $6.86 $535,873 - $1.09 Million	159,013 Added 7.4%	2,307,834 $15 Million
Q3 2023 Nov 13, 2023	BUY	$4.7 - $8.55 $3.12 Million - $5.68 Million	664,167 Added 44.74%	2,148,821 $10.8 Million
Q2 2023 Aug 11, 2023	BUY	$7.35 - $13.29 $199,920 - $361,488	27,200 Added 1.87%	1,484,654 $13 Million
Q1 2023 May 12, 2023	BUY	$7.91 - $12.0 $5.6 Million - $8.49 Million	707,430 Added 94.32%	1,457,454 $17.3 Million
Q4 2022 Feb 10, 2023	BUY	$4.62 - $10.18 $3.47 Million - $7.64 Million	750,024 New	750,024 $7.64 Million

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.